Cystinosis Results Help Rebuild Confidence In AvroBio’s Gene Therapy

Potential Registrational Study To Start This Year

The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.

Avrobio
• Source: Shutterstock

AvroBio has presented positive updated Phase I/II data of its AVR-RD-04 gene therapy in cystinosis, helping to lift investor sentiment around the company and its lentiviral-based gene therapy platform.

The company’s share price hit rock bottom last year after it abandoned Fabry disease gene therapy candidate AVR-RD-01, but the...

More from Alimentary/Metabolic

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.